Immune checkpoint inhibitors (ICIs), such as those targeting PD-L1, PD-1, and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), have been investigated across multiple tumor types and have shown significant benefits in clinical studies10. This evidence concerns the gene CTLA4 and neoplasm.